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ril 1, 2013.he aim of this study was to determine the relationship between B-type natriuretic peptide (BNP) and survival in
patients with hypertrophic cardiomyopathy.Background Natriuretic peptides are released in response to neurohormonal activation, myocardial stretch, and wall tension and
therefore reﬂect hemodynamic derangements.Methods A total of 772 patients with hypertrophic cardiomyopathy had BNP obtained in conjunction with echocardiography
and clinical evaluation, inclusive of cardiopulmonary exercise evaluation in 429 patients (56%).Results Survival free of all-cause mortality was lower across increasing levels of BNP (log-rank test, p ¼ 0.002). Three-year
survival by tertile was 99.2% (95% conﬁdence interval: 94.3% to 99.9%; BNP level 98 pg/ml), 94.8% (95%
conﬁdence interval: 88.2% to 97.8%; BNP level, >98 to <298 pg/ml), and 89.9% (95% conﬁdence interval: 82.0%
to 94.5%; BNP level 298 pg/ml). Compared with patients in the ﬁrst tertile, the hazard ratios for death in the
second and third tertiles were 4.88 (p ¼ 0.006) and 6.98 (p ¼ 0.0003), respectively. This relationship persisted
in patients without resting obstructive physiology (n ¼ 497, p ¼ 0.01). BNP levels were related to New York
Heart Association functional status (p < 0.0001) and the subsequent need for septal reduction therapy in
follow-up (p ¼ 0.04).Conclusions In this large cohort of patients with hypertrophic cardiomyopathy, BNP was an independent predictor of morbidity
and mortality. (J Am Coll Cardiol 2013;61:2456–60) ª 2013 by the American College of Cardiology FoundationHypertrophic cardiomyopathy (HCM) is characterized by
cardiomyocyte hypertrophy, myoﬁbrillar disarray, and in-
terstitial ﬁbrosis, resulting in regional and global abnormal
generation of contractile force and hindered relaxation (1).
Although the vast majority of patients have normal
longevity, progressive and drug-refractory heart failure can
develop in others. Given this varied clinical spectrum,
symptom assessment and prognostication can be challenging
in these patients.
B-type natriuretic peptide (BNP) is a biologically active
peptide synthesized and released primarily from cardiac
myocytes as a response to neurohormonal activation,
myocardial stretch, and wall tension (2). Circulating plasma
BNP levels are elevated in numerous cardiac pathologies in
the presence of hemodynamic overload and increased cardiac
ﬁbrosis (3–5). The use of natriuretic peptides is a well-
established tool in the diagnosis, prognosis, and manage-
ment of patients with systolic dysfunction (6,7). However,
there is a paucity of data on the clinical signiﬁcance,edicine, Division of Cardiovascular Diseases,
chester, Minnesota. The authors have reported
t to the contents of this paper to disclose.
3; revised manuscript received March 21, 2013,particularly with regard to survival, of these biomarkers in
patients with HCM (8).
Accordingly, the objective of the present investigation was
to determine the prognostic utility of BNP in patients with
HCM.
Methods
Patient selection. The study population consisted of 772
patients with HCM evaluated at theMayo Clinic (Rochester,
Minnesota) between January 2006 and May 2009. The
diagnosis of HCM was based on the presence of myocardial
hypertrophy in the absence of local or systemic etiologies
(9,10). All patients had a plasma BNP level obtained for
clinical purposes at the time of evaluation. Plasma BNP
was measured by ﬂuorescence immunoassay (Biosite Diag-
nostics [now Alere, Inc.], San Diego, California) using
a Beckman Coulter DXI 800 instrument. When possible,
BNP levels were processed immediately after phlebotomy.
Otherwise, samples were spun down and plasma frozen
until the sample was analyzed (no more than 3 days). The
precision, sensitivity, and stability of this particular BNP
assay were previously described (11). Comprehensive resting
2-dimensional transthoracic echocardiography was per-
formed in all patients, as previously described (12).
Abbreviations
and Acronyms
BNP = B-type natriuretic
peptide
CI = conﬁdence interval
HCM = hypertrophic
cardiomyopathy
IQR = interquartile range
LV = left ventricular
SRT = septal reduction
therapy
VO2 = oxygen consumption
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2457Symptom-limited graded exercise testing was performed
using a motor-driven treadmill (Quinton, Seattle, Wash-
ington) with an accelerated Naughton protocol. Continuous
electrocardiographic monitoring (Marquette Electronics,
Milwaukee, Wisconsin) and breath-to-breath metabolic
measurement (Medical Graphics, St. Paul, Minnesota) were
used, as previously described (13). All patients provided
consent for use of their medical records for research purposes
in accordance withMinnesota law and an institutional review
board–approved study.
Statistical analysis. Continuous variables are expressed as
mean  SD; BNP and left ventricular (LV) outﬂow tract
were not normally distributed and are reported as median
with interquartile range. Correlations of continuous variables
were examined using Spearman rank correlation coefﬁcients.
Comparison of continuous variables was performed using
the Wilcoxon rank sum test. Wilcoxon signed rank tests
were used for comparison of repeated measures of BNP. For
comparisons of contingency variables, the Fisher exact test
was used. For multivariate modeling, BNP was transformed
using log(BNP). Multivariable linear regression modeling
with mixed-direction stepwise selection method (p value
threshold to enter ¼ 0.15; to leave, 0.05) was used to
determine clinical predictors of log(BNP). Survival free of
the study endpoints (all-cause mortality and combined
endpoint of mortality and occurrence of septal reduction
therapy [SRT]) were assessed using Kaplan-Meier survival
curves, with log-rank test p values reported. Cox propor-
tional hazard analysis was performed to determine the
relationship of BNP with study endpoints.Table 1 Baseline Characteristics








Implantable cardioverter-deﬁbrillator 174 (23)
Family history of HCM 253 (33)
Family history of SCD 178 (23)
Previous myectomy 97 (13)
Previous septal ablation 40 (5)
Medications
Beta-receptor antagonist 641 (83)
Calcium channel blocker 339 (44)
ACE inhibitor/ARB 226 (29)
Amiodarone 80 (10)
Disopyramide 79 (10)
Systolic blood pressure, mm Hg 119  17
Diastolic blood pressure, mm Hg 71  11
Heart rate, beats/min 64  11
Body mass index, kg/m2 30.0  6.2
Values are mean  SD or n (%).
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; HCM ¼ hypertrophic
cardiomyopathy; NYHA ¼ New York Heart Association; SCD ¼ sudden cardiac death.Results
Study population. Baseline char-
acteristics of the study population
are listed in Tables 1 and 2. Mean
age was 52  16 years (62%
male). The vast majority had mild
or no symptoms (61% were New
York Heart Association [NYHA]
functional class I or II). Median
BNP for the entire study pop-
ulation was 177.5 (interquartile
range [IQR]: 71 to 395) pg/ml.
BNP was associated with mul-
tiple clinical and echocardiographic parameters, although the
correlations with these clinical variables were modest
(Spearman r range, 0.02 to 0.45) (Table 3). Multivariate
linear regression modeling of log(BNP) (2.2  0.5 log [pg/
ml]) using variables from Table 3 revealed multiple signiﬁcant
covariates (model R ¼ 0.69): septal thickness (p < 0.0001),
medial E/e0 (p ¼ 0.0001), resting LV outﬂow tract gradient
(p < 0.0001), right ventricular systolic pressure (p ¼ 0.0006),
ejection fraction (p ¼ 0.0008), moderate or greater mitral
regurgitation (p ¼ 0.005), body mass index (p ¼ 0.006), age
(p ¼ 0.004), E/A (peak early diastolic velocity/peak late
diastolic velocity) ratio (p ¼ 0.003), and left atrial volume
index (p ¼ 0.02).
Cardiopulmonary exercise was performed in 429 patients
(Table 4). BNP was related to both peak oxygen
consumption (VO2) (Spearman r ¼ 0.44, p < 0.0001) and
percent predicted VO2 achieved during cardiopulmonary
exercise testing (Spearman r ¼ 0.33, p < 0.0001). Of 264
patients with mild or no symptoms (NYHA functional class
I or II) who underwent exercise testing, the BNP level wasTable 2 Echocardiography Data
LV outﬂow tract gradient, mm Hg 13 (0–49)
Resting obstruction, >30 mm Hg 275 (36)
LV ejection fraction, % 68  8
LV ejection fraction <50% 19 (2)
LV end-diastolic dimension, mm 46  6
Anteroseptal wall thickness, mm 18  6
Posterior wall thickness, mm 13  3
Moderate or severe mitral regurgitation 101 (13)
Estimated right ventricular systolic pressure, mm Hg 35  11
Mitral E velocity, cm/s 0.8  0.3
Mitral A velocity, cm/s 0.7  0.3
E/A ratio 1.4  0.7
Medial e0 , cm/s 0.06  0.02
Lateral e0 , cm/s 0.08  0.03
Medial E/e0 ratio 17.3  8.3
Lateral E/e0 ratio 12.5  6.7
Left atrial volume index, cm3/m3 47  19
Index >40 cm3/m3 424 (55)
Values are median (interquartile range), n (%), or mean  SD.
A ¼ peak late diastolic velocity; E ¼ peak early diastolic velocity; LV ¼ left ventricular; Medial e0
and lateral e0 ¼ annular tissue Doppler signals.
Table 3
Relationship of B-Type Natriuretic Peptide to
Clinical and Echocardiographic Variables
Variable Spearman r p Value
Age, yrs 0.12 0.07
Body mass index, kg/m2 0.13 0.003
NYHA functional classes III–IV d <0.0001
Systolic blood pressure, mm Hg 0.14 0.003
LV outﬂow tract gradient, mm Hg 0.26 <0.0001
Resting obstruction d <0.0001
Moderate or severe mitral regurgitation d <0.0001
LV ejection fraction, % 0.02 0.0002
Ejection fraction <50% d <0.0001
LV end-diastolic dimension, mm 0.14 0.002
Anteroseptal wall thickness, mm 0.33 <0.0001
Posterior wall thickness, mm 0.17 <0.0001
Estimated right ventricular systolic pressure,
mm Hg
0.44 <0.0001
E/A ratio 0.18 <0.0001
Medial E/e0 ratio 0.44 <0.0001
Lateral E/e0 ratio 0.34 <0.0001
Left atrial volume index, cm3/m3 0.45 <0.0001
Correlations of continuous variables performed with simple linear regression analysis; Wilcoxon
signed-rank tests were used for comparison of B-type natriuretic peptide and nominal variables.
Abbreviations as in Tables 1 and 2.
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2458signiﬁcantly higher in minimally symptomatic patients with
a low percent predicted VO2 (<80%; n ¼ 185) compared
with those with a percent predicted VO2 80% (n ¼ 89)
(154 [IQR: 57.5 to 365.5] pg/ml vs. 97 [IQR: 43 to 239]
pg/ml; Wilcoxon p ¼ 0.04).
Survival. Overall, 30 patients died in follow-up (mean
follow-up, 1.7  1.9 years). Patients who died had a higher
BNP level than survivors (288.5 [IQR: 214 to 573.8] pg/ml
vs. 168.5 [IQR: 68.8 to 387.3] pg/ml; Wilcoxon p ¼ 0.002).
Survival free of all-cause mortality was lower with increasing
tertiles of BNP (log-rank p ¼ 0.002) (Fig. 1A). Three-year
survival by tertile was 99.2% (95% conﬁdence interval [CI]:
94.3% to 99.9%), 94.8% (95% CI: 88.2% to 97.8%), and
89.9% (95% CI: 82.0% to 94.5%). Compared with patients
in the ﬁrst tertile, the hazard ratios for death in the
second and third tertiles were 4.88 (p ¼ 0.006) and 6.98
(p ¼ 0.0003), respectively. BNP also was a signiﬁcant
predictor of death in patients without obstructive physiology
at rest (n ¼ 497, p ¼ 0.01).
Of the 30 deaths, the cause of death was available for
14 (47%). Five of 14 patients died of noncardiac causes,
4 (29%) had sudden cardiac death, 4 (29%) had a cerebro-
vascular accident, and 1 (7%) died secondary to a heartTable 4 Cardiopulmonary Exercise Data
Exercise capacity, METs 7.3  2.7
Functional aerobic capacity, % 70.2  20.8
Peak double product, beats/min  mm Hg 20,218  7,107
Peak VO2, ml/kg/min 20.7  7.2
VO2 predicted, % 65.5  19.3
Values are mean  SD. Cardiopulmonary exercise performed in 429 patients (56%).
METs ¼ metabolic equivalents; VO2 ¼ oxygen consumption.failure exacerbation. The incidence per 100 person-year
follow-up of all-cause mortality was 2.29 (95% CI: 1.47 to
3.52). For the combined endpoint of sudden cardiac death
and unknown cause of death, the incidence per 100 person-
year follow-up was 1.45 (95% CI: 0.80 to 2.43).
Septal reduction therapy. Overall, 471 patients had no
history of SRT and no planned surgical procedures within
30 days of biomarker assessment. Of these 471 patients,
there were 16 deaths and 69 patients who later underwent
SRT in follow-up (66 myectomy, 3 alcohol septal ablation).
Patients who later required SRT had a signiﬁcantly higher
BNP at the time of initial assessment (273 [IQR: 129
to 418.5] pg/ml vs. 138.5 [IQR: 50.8 to 343] pg/ml,
Wilcoxon p ¼ 0.0002). Increasing tertiles of BNP were
associated with lower survival free of need for SRT (3-year
Kaplan-Meier estimates by tertile: 88.6% [95% CI: 81.2%
to 93.3%], 74.2% [95% CI: 63.9% to 82.3%], and 67.8%
[95% CI: 57.5% to 76.7%]; log-rank p ¼ 0.001) (Fig. 1B),
and lower survival free of the combined endpoint of death
or need for SRT (3-year Kaplan-Meier estimates by tertile:
87.6% [95% CI: 80.0% to 92.6%], 71.6% [95% CI: 61.1%
to 80.2%], and 60.9% [95% CI: 50.4% to 70.6%]; log-rank
p < 0.0001) (Fig. 1C). Compared with patients in the ﬁrst
tertile, the hazard ratios for death or need for SRT in the
second and third tertiles were 2.56 (p ¼ 0.002) and 3.89
(p < 0.0001), respectively. Of note, biomarker ascertain-
ment before and after SRT was performed in 76 patients,
with post-procedural BNP assessed 378 days (IQR: 226 to
522 days) after SRT. BNP signiﬁcantly decreased from
234 pg/ml (IQR: 123 to 507.8 pg/ml) to 151 pg/ml (IQR:
92.3 to 313 pg/ml) in these patients (Wilcoxon p ¼ 0.009).
Discussion
The present investigation is the largest longitudinal study of
BNP in patients with HCM. We demonstrate that increases
in BNP are associated with adverse survival and a greater
need for subsequent SRT. These data demonstrate the
potential clinical utility of BNP in HCM and suggest that
these biomarkers may be used to help with prognostication
of these patients.
Studies of BNP in HCM to date have largely focused on
correlation of BNP with echocardiographic parameters or
functional class (14–20). Our ﬁndings (Table 3) corroborate
these smaller studies. However, the prognostic impact of BNP
on survival in HCM remains poorly studied, likely given
mortality rates similar to those of the general U.S. adult pop-
ulation for all causes (1). Our large cohort of patients with
HCM shows that BNP is an independent predictor of survival,
even in patients without severe obstruction, and allows further
prognostication during assessment of patients with HCM.
Studies assessing BNP and cardiopulmonary exercise
in HCM have presented mixed results (15,16,21,22). We
present the largest analysis to date of cardiopulmonary
exercise data and BNP with HCM and demonstrate
signiﬁcant correlation of both peak VO2 and the percent
Figure 1 B-Type Natriuretic Peptide and Survival
Increasing tertiles of B-type natriuretic peptide were associated with higher mortality (log-rank p ¼ 0.002) (A), greater risk of future septal reduction therapy (SRT)
(log-rank p ¼ 0.001) (B), and the combined endpoint of death or need for subsequent SRT (log-rank p < 0.0001) (C).
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increased in patients with poor performance on cardiopul-
monary exercise tolerance despite minimal symptoms.
Assessment of BNP may provide insight into signiﬁcant
hemodynamic perturbations requiring further scrutiny,
regardless of symptom status.
Hemodynamics in HCM are characteristically labile,
particularly LV outﬂow tract obstruction (23,24). Increases
in BNP reﬂect a common end pathway to ﬂuctuating
hemodynamic strain. As such, BNP provides insight into
the hemodynamic burden on cardiac chambers and the
associated adverse ventricular remodeling. Our data reveal a
signiﬁcant decrease in BNP after surgical relief of obstruc-
tion. The impact of this change on long-term prognosis
remains unclear and requires further study.
Study limitations. The present study is a retrospective
analysis, with known inherent limitations, including
selection bias. Of note, the majority of the patients wereminimally symptomatic or asymptomatic (61% NYHA
functional class I or II). Although our study represents the
largest longitudinal study of BNP in HCM, the overall
mortality rate was only 2.3% per year, and the cause of death
could not be determined in a number of patients. Thus, our
ability of BNP to predict HCM-related death was limited.
Nevertheless, there was a clear relationship between BNP
and survival free of all-cause mortality, a hard endpoint in
previous HCM publications (25,26).
Conclusions
The present investigation provides insight into the clinical
applicability of BNP in a large population with HCM.
Increases in BNP have the potential to identify poor
cardiopulmonary exercise tolerance in minimally symptom-
atic patients and help to identify nonobstructive patients
with higher mortality. Routine assessment of natriuretic
Geske et al. JACC Vol. 61, No. 24, 2013
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2460peptides may be useful in minimally symptomatic patients
for prognostic stratiﬁcation. Given the diverse range of
clinical phenotypes associated with HCM, our ﬁndings
suggest that BNP may have incremental beneﬁt for the
clinical evaluation and prognostication of these patients.Reprint requests and correspondence: Dr. Paul Sorajja, Mayo
Clinic College of Medicine, 200 First Street SW, Rochester,
Minnesota 55905. E-mail: sorajja.paul@mayo.edu.REFERENCES
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